Pharma

Adverum, Gene Therapy, and AMD

Adverum, Gene Therapy, and AMD

By Steve Lenier | March 25, 2020

Adverum, a company pioneering novel gene therapies for ocular diseases, believes a gene therapy treatment for wet age-related macular degeneration (AMD) can reduce treatment burden…

Read More
CRISPR and inherited retinal disease

CRISPR and inherited retinal disease

By Keith Croes | March 18, 2020

Once again the eye proved to be the pioneer target in a new gene therapy approach, with the use in February of an agent utilizing…

Read More
2020’s Potential Retina Milestones

2020’s Potential Retina Milestones

By Rich Kirkner | February 26, 2020

As reports of intraocular inflammation and vasculitis have cast caution onto the uptake of the newest approved anti-VEGF drug, Novartis’ Beovu (brolucizumab), the quest to…

Read More
Glaucoma 360: Promising data as the industry considers value

Glaucoma 360: Promising data as the industry considers value

By Heather Johnson | February 12, 2020

“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF)…

Read More
Ranibizumab More Cost-Effective Than PRP

Ranibizumab More Cost-Effective Than PRP

By Vanessa Caceres | February 5, 2020

The use of ranibizumab 0.5 mg for proliferative diabetic retinopathy (PDR) compared with panretinal photocoagulation (PRP) appeared to be more cost effective for patients with…

Read More
Soft CL slows myopia in children

Soft CL slows myopia in children

By Keith Croes | January 22, 2020

Globally, the myopia market may be worth upwards of $28 billion by 2026, with single prescription corrective lenses holding a significant market share, according to…

Read More
Lucentis and Eylea patent expirations in the micro-crystal ball

Lucentis and Eylea patent expirations in the micro-crystal ball

By Keith Croes | January 14, 2020

Over the past 10 years, the Dow Jones Industrial Average has seen a 10-year climb with small calendar-year dips seen in 2015 (-2.23%) and 2018…

Read More
Innovations a Highlight at Dry Eye Breakout Session

Innovations a Highlight at Dry Eye Breakout Session

By Steve Lenier | January 8, 2020

The dry eye disease (DED) market is expected to have an annual compound growth rate of 4.5% between 2017 and 2025, which should help it…

Read More
BioGenware’s Speculet Seeks to Improve the Patient Experience

BioGenware’s Speculet Seeks to Improve the Patient Experience

By Steve Lenier | December 18, 2019

For those undergoing intravitreal injections (and there are about 22 million of these performed yearly worldwide), a common complaint is that the speculum is uncomfortable,…

Read More
We’ve Got Your BAK

We’ve Got Your BAK

By Michelle Dalton | December 11, 2019

Imagine a world where you could use as much preservative as you needed in a prescription eye drop without ever having to worry it would…

Read More
CorneaGen Aims to End Corneal Blindness

CorneaGen Aims to End Corneal Blindness

By Vanessa Caceres | December 4, 2019

CorneaGen’s approach to treating corneal blindness is to prevent it from ever occurring, said Monty Montoya, president and CEO, who added no other organization has…

Read More
RegenxBio sues FDA over clinical hold

RegenxBio sues FDA over clinical hold

By Keith Croes | November 27, 2019

Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.